SCHEMBL19956897

SCHEMBL19956897

CNc1c(NCc2ccccc2)c(=O)c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPKAPK2 P49137 1/20 0.57
KMT2A Q03164 5/20 0.50
POLB P06746 2/20 0.50
RAD52 P43351 1/20 0.50
HDAC1 Q13547 1/20 0.50
HSD17B10 Q99714 1/20 0.48
CXCR2 P25025 1/20 0.47
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47
CYP3A4 P08684 1/20 0.47
HTT P42858 1/20 0.44
HPGD P15428 2/20 0.43
ALDH1A1 P00352 2/20 0.43
CHEK1 O14757 1/20 0.43
CHEK2 O96017 1/20 0.43
PRKACA P17612 1/20 0.43
RPS6KB1 P23443 1/20 0.43
GSK3A P49840 1/20 0.43
GSK3B P49841 1/20 0.43
RPS6KA3 P51812 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3747115 0.90 MAPKAPK2 (0.66) MAPKAPK2KMT2APOLBRAD52HDAC1
SCHEMBL19956899 0.81 MEN1 (0.63) KMT2APOLBCXCR2KDM4EGAA
SCHEMBL19956894 0.81 PRKACA (0.59) MAPKAPK2POLBHDAC1KDM4EMAPT
SCHEMBL19956915 0.81 CHEK1 (0.59) KMT2AHDAC1HSD17B10ALDH1A1CHEK1
SCHEMBL13887501 0.81 MAPKAPK2 (0.53) MAPKAPK2KMT2APOLBRAD52HDAC1
SCHEMBL10208779 0.80 CHEK2 (0.43) MAPKAPK2KMT2AHDAC1CXCR2MAPT
SCHEMBL13156401 0.80 NPC1 (0.43) MAPKAPK2HDAC1CXCR2CYP3A4ALDH1A1
SCHEMBL7894067 0.79 LOXL2 (0.59) MAPKAPK2POLBKDM4EHPGDALDH1A1
SCHEMBL31421538 0.78 HDAC1 (0.55) MAPKAPK2KMT2APOLBRAD52HDAC1
SCHEMBL31377177 0.78 HDAC1 (0.55) MAPKAPK2KMT2APOLBRAD52HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same Guangdong Raynovent Biotech Co., Ltd. (CN) 2020-05-19 US disclosed
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Guangdong Raynovent Biotech Co., Ltd. (CN) 2019-04-25 US disclosed
EP-3293177-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2018-03-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190119217-A1 TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME ABL1, LCK, ERBB2 MAPKAPK2 167/4885KMT2A 1030/4885POLB 2992/4885
US-10654808-B2 Tyrosine kinase inhibitor and pharmaceutical composition comprising same ABL1, LCK, ERBB2 MAPKAPK2 167/4885KMT2A 1030/4885POLB 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.